JFS Wealth Advisors
RCUS icon

JFS Wealth Advisors’s Arcus Biosciences RCUS Stock Holding History

JFS Wealth Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$388 Buy
15
+7
+88% +$197 ﹤0.01% 1953
2026
Q2 		$247 Buy
+8
New +$198 ﹤0.01% 2109
2024
Q4 		– Sell
-7
Closed -$108 – 1985
2024
Q3 		$108 Sell
7
-1
-13% -$16 ﹤0.01% 1900
2024
Q2 		$122 Hold
8
– – ﹤0.01% 1920
2024
Q1 		$152 Buy
8
+1
+14% +$17 ﹤0.01% 1914
2023
Q4 		$134 Sell
7
-4
-36% -$64 ﹤0.01% 1938
2023
Q3 		$198 Buy
11
+2
+22% +$40 ﹤0.01% 1862
2023
Q2 		$183 Buy
9
+7
+350% +$133 ﹤0.01% 1885
2023
Q1 		$37 Sell
2
-14
-88% -$268 ﹤0.01% 1933
2022
Q4 		$331 Buy
16
+6
+60% +$165 ﹤0.01% 1793
2022
Q3 		$0 Buy
10
+8
+400% +$212 ﹤0.01% 1892
2022
Q2 		$0 Sell
2
-2
-50% -$49 ﹤0.01% 1902
2022
Q1 		$0 Buy
4
+2
+100% +$67 ﹤0.01% 1939
2021
Q4 		$0 Buy
+2
New +$78 ﹤0.01% 1849

Other funds holding RCUS

Gilead Sciences
Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

JFS Wealth Advisors's RCUS Position: Q3 2026 in Review

JFS Wealth Advisors increased its Arcus Biosciences (RCUS) stake by 88% in Q3 2026, buying an estimated $197 and bringing the position to 15 shares worth $388. The position accounts for ﹤0.01% of the portfolio, ranked #1953.

JFS Wealth Advisors first reported a position in RCUS in Q4 2021 and has held it in 14 quarters since. 111 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.

  • JFS Wealth Advisors held 15 shares of Arcus Biosciences worth $388 as of Q3 2026.
  • JFS Wealth Advisors bought 7 Arcus Biosciences shares in Q3 2026, an estimated $197.
  • Arcus Biosciences made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q3 2026, its #1953 holding.
  • JFS Wealth Advisors first reported a position in Arcus Biosciences in Q4 2021 and has held it in 14 quarters since.
  • 111 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.

Based on JFS Wealth Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.